Involvement of the immune system in idiosyncratic drug reactions

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 1, 2011, Pages 47-59

  Zhang, Xiachu ^a   Liu, Feng ^a   Chen, Xin ^a   Zhu, Xu ^a   Uetrecht, Jack ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Autoimmunity; Danger hypothesis; Drug induced liver injury; Hapten hypothesis; Idiosyncratic drug reactions; Mitochondrial injury

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA INTERFERON; AMPICILLIN; ANTIBODY; AZACITIDINE; CARBAMAZEPINE; CLOZAPINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; HALOTHANE; HAPTEN; HYDRALAZINE; ISONIAZID; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PENICILLIN G; PROCAINAMIDE; QUINIDINE; QUININE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SULFAMETHOXAZOLE; SULFONAMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG;

ADVERSE DRUG REACTION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BIPOLAR DISORDER; CELL ACTIVATION; EPIGENETICS; HEMOLYTIC ANEMIA; HUMAN; HYPOTHESIS; IDIOSYNCRATIC DRUG REACTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; LIVER INJURY; LIVER MITOCHONDRION; LIVER TOXICITY; LUPUS LIKE SYNDROME; LUPUS VULGARIS; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PSORIASIS; REVIEW; SCHIZOPHRENIA; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VASCULITIS;

EID: 79952767321     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RV-085     Document Type: Review

References (135)

1. Uetrecht, J.: Idiosyncratic drug reactions: current understanding. Annu. Rev. Pharmacol. Toxicol., 47: 513-539 (2007).
2. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J. et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ, 329(7456): 15-19 (2004).
3. Uetrecht, J.: Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol., 21(1): 84-92 (2008).
4. Lee, W. M.: Drug-induced hepatotoxicity. N. Engl. J. Med., 349(5): 474-485 (2003).
5. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M. and Bor, D. H.: Timing of new black box warnings and withdrawals for prescription medications. JAMA, 287(17): 2215-2220 (2002).
6. Lammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E. and Chalasani, N.: Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology, 47(6): 2003-2009 (2008).
7. Bersoff-Matcha, S. J., Miller, W. C., Aberg, J. A., van Der Horst, C., Hamrick, H. J., Jr., Powderly, W. G. et al.: Sex differences in nevirapine rash. Clin. Infect. Dis., 32(1): 124-129 (2001).
8. Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C. et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet, 359(9308): 727-732 (2002).
9. Martin, A. M., Nolan, D., Gaudieri, S., Almeida, C. A., Nolan, R., James, I. et al.: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. U.S.A., 101(12): 4180-4185 (2004).
10. Uetrecht, J.: Immune-mediated adverse drug reactions. Chem. Res. Toxicol., 22(1): 24-34 (2009).
11. Landsteiner, K. and Jacobs, J.: Studies on the sensitization of animals with simple chemical compounds. J. Exp. Med., 61(5): 643-656 (1935).
12. Janeway, C.: Immunobiology: the immune system in health and disease. 6th ed. New York, Garland Science, 2005.
13. Brodie, B. B., Reid, W. D., Cho, A. K., Sipes, G., Krishna, G. and Gillette, J. R.: Possible mechanism of liver necrosis caused by aromatic organic compounds. Proc. Natl. Acad. Sci. U.S.A., 68(1): 160-164 (1971).
14. Mitchell, J. R., Jollow, D. J., Gillette, J. R. and Brodie, B. B.: Drug metabolism as a cause of drug toxicity. Drug Metab. Dispos., 1(1): 418-423 (1973).
15. Parker, C. W., Deweck, A. L., Kern, M. and Eisen, H. N.: The preparation and some properties of penicillenic acid derivatives relevant to penicillin hypersensitivity. J. Exp. Med., 115: 803-819 (1962).
16. Vergani, D., Mieli-Vergani, G., Alberti, A., Neuberger, J., Eddleston, A. L., Davis, M. et al.: Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med., 303(2): 66-71 (1980).
17. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A. and Baillie, T. A.: Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol., 17(1): 3-16 (2004).
18. Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y. et al.: A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos., 37(9): 1970-1977 (2009).
19. Kindmark, A., Jawaid, A., Harbron, C. G., Barratt, B. J., Bengtsson, O. F., Andersson, T. B. et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J., 8(3): 186-195 (2008).
20. Uetrecht, J. P.: New concepts in immunology relevant to idiosyncratic drug reactions: the údanger hypothesisû and innate immune system. Chem. Res. Toxicol., 12(5): 387-395 (1999).
21. Medzhitov, R. and Janeway, C. A., Jr.: Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol., 9(1): 4-9 (1997).
22. Matzinger, P.: Tolerance, danger, and the extended family. Annu. Rev. Immunol., 12: 991-1045 (1994).
23. Seguin, B. and Uetrecht, J.: The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol., 3(4): 235-242 (2003).
24. Levy, M.: Role of viral infections in the induction of adverse drug reactions. Drug Saf., 16(1): 1-8 (1997).
25. Pullen, H., Wright, N. and Murdoch, J. M.: Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet, 2(7527): 1176-1178 (1967).
26. Fischl, M. A., Dickinson, G. M. and La Voie, L.: Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA, 259(8): 1185- 1189 (1988).
27. Ellrodt, A. G., Murata, G. H., Riedinger, M. S., Stewart, M. E., Mochizuki, C. and Gray, R.: Severe neutropenia associated with sustained-release procainamide. Ann. Intern. Med., 100(2): 197-201 (1984).
28. Harris, H. E. and Raucci, A.: Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep., 7(8): 774-778 (2006).
29. Lotze, M. T. and Tracey, K. J.: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol., 5(4): 331-342 (2005).
30. Kokkola, R., Andersson, A., Mullins, G., Ostberg, T., Treutiger, C. J., Arnold, B. et al.: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand. J. Immunol., 61(1): 1-9 (2005).
31. Youn, J. H. and Shin, J. S.: Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol., 177(11): 7889-7897 (2006).
32. Antoine, D. J., Williams, D. P., Kipar, A., Jenkins, R. E., Regan, S. L., Sathish, J. G. et al.: High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci., 112(2): 521-531 (2009).
33. Ehrchen, J. M., Sunderkotter, C., Foell, D., Vogl, T. and Roth, J.: The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J. Leukoc. Biol., 86(3): 557-566 (2009).
34. Wolf, R., Lewerenz, V., Buchau, A. S., Walz, M. and Ruzicka, T.: Human S100A15 splice variants are differentially expressed in inflammatory skin diseases and regulated through Th1 cytokines and calcium. Exp. Dermatol., 16(8): 685-691 (2007).
35. Elsner, L., Flugge, P. F., Lozano, J., Muppala, V., Eiz-Vesper, B., Demiroglu, S. Y. et al.: The endogenous danger signals HSP70 and MICA cooperate in the activation of cytotoxic effector functions of NK cells. J. Cell. Mol. Med., 14(4): 992-1002 (2010).
36. Miller-Graziano, C. L., De, A., Laudanski, K., Herrmann, T. and Bandyopadhyay, S.: HSP27: an anti-inflammatory and immunomodulatory stress protein acting to dampen immune function. Novartis Found. Symp., 291: 196-208; discussion 208-211, 221- 224 (2008).
37. Pichler, W. J.: Pharmacological interaction of drugs with antigenspecific immune receptors: the p-i concept. Curr. Opin. Allergy Clin. Immunol., 2(4): 301-305 (2002).
38. Chen, X., Tharmanathan, T., Mannargudi, B., Gou, H. and Uetrecht, J. P.: A study of the specificity of lymphocytes in nevirapine-induced skin rash. J. Pharmacol. Exp. Ther., 331(3): 836-841 (2009).
39. Castrejon, J. L., Berry, N., El-Ghaiesh, S., Gerber, B., Pichler, W. J., Park, B. K. et al.: Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J. Allergy Clin. Immunol., 125(2): 411-418.e4 (2010).
40. Ramos-Casals, M., Roberto Perez, A., Diaz-Lagares, C., Cuadrado, M. J. and Khamashta, M. A.: Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun. Rev., 9(3): 188-193 (2010).
41. Gonzalez-Lopez, M. A., Martinez-Taboada, V. M., Gonzalez- Vela, M. C., Fernandez-Llaca, H. and Val-Bernal, J. F.: Newonset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br. J. Dermatol., 158(5): 1146-1148 (2008).
42. Mielke, F., Schneider-Obermeyer, J. and Dorner, T.: Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann. Rheum. Dis., 67(7): 1056-1057 (2008).
43. Szyf, M.: Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol., 49: 243-263 (2009).
44. Sekigawa, I., Okada, M., Ogasawara, H., Kaneko, H., Hishikawa, T. and Hashimoto, H.: DNA methylation in systemic lupus erythematosus. Lupus, 12(2): 79-85 (2003).
45. Dong, E., Nelson, M., Grayson, D. R., Costa, E. and Guidotti, A.: Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl. Acad. Sci. U.S.A., 105(36): 13614-13619 (2008).
46. Tesfa, D., Keisu, M. and Palmblad, J.: Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am. J. Hematol., 84(7): 428-434 (2009).
47. Khan, R., Schmidt-Mende, J., Karimi, M., Gogvadze, V., Hassan, M., Ekstrom, T. J. et al.: Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp. Hematol., 36(2): 149-157 (2008).
48. Uetrecht, J.: Drug metabolism by leukocytes and its role in druginduced lupus and other idiosyncratic drug reactions. Crit. Rev. Toxicol., 20(4): 213-235 (1990).
49. Sanderson, J. P., Naisbitt, D. J., Farrell, J., Ashby, C. A., Tucker, M. J., Rieder, M. J. et al.: Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J. Immunol., 178(9): 5533-5542 (2007).
50. Rhodes, J.: Covalent chemical events in immune induction: fundamental and therapeutic aspects. Immunol. Today, 17(9): 436-441 (1996).
51. Li, J., Mannargudi, B. and Uetrecht, J. P.: Covalent binding of penicillamine to macrophages: implications for penicillamineinduced autoimmunity. Chem. Res. Toxicol., 22(7): 1277-1284 (2009).
52. Li, J. and Uetrecht, J. P.: D-penicillamine-induced autoimmunity: relationship to macrophage activation. Chem. Res. Toxicol., 22(9): 1526-1533 (2009).
53. Shenton, J. M., Teranishi, M., Abu-Asab, M. S., Yager, J. A. and Uetrecht, J. P.: Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem. Res. Toxicol., 16(9): 1078-1089 (2003).
54. Chen, J., Mannargudi, B. M., Xu, L. and Uetrecht, J.: Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chem. Res. Toxicol., 21(9): 1862- 1870 (2008).
55. Borchers, A. T., Keen, C. L. and Gershwin, M. E.: Drug-induced lupus. Ann. N. Y. Acad. Sci., 1108: 166-182 (2007).
56. Pichler, W. J.: Drug-induced autoimmunity. Curr. Opin. Allergy Clin. Immunol., 3(4): 249-253 (2003).
57. Fritzler, M. J. and Tan, E. M.: Antibodies to histones in druginduced and idiopathic lupus erythematosus. J. Clin. Invest., 62: 560-567 (1978).
58. Wiik, A.: Drug-induced vasculitis. Curr. Opin. Rheumatol., 20(1): 35-39 (2008).
59. Vasoo, S.: Drug-induced lupus: an update. Lupus, 15(11): 757-761 (2006).
60. Crowson, A. N., Brown, T. J. and Magro, C. M.: Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions: implications for management. Am. J. Clin. Dermatol., 4(6): 407-428 (2003).
61. Fritzler, M. J.: Drugs recently associated with lupus syndromes. Lupus, 3(6): 455-459 (1994).
62. Ramos-Casals, M., Brito-Zeron, P., Soto, M. J., Cuadrado, M. J. and Khamashta, M. A.: Autoimmune diseases induced by TNFtargeted therapies. Best Pract. Res. Clin. Rheumatol., 22(5): 847-861 (2008).
63. Woosley, R. L., Drayer, D. E., Reidenberg, M. M., Nies, A. S., Carr, K. and Oates, J. A.: Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N. Engl. J. Med., 298(21): 1157-1159 (1978).
64. Yung, R. L., Johnson, K. J. and Richardson, B. C.: New concepts in the pathogenesis of drug-induced lupus. Lab. Invest., 73(6): 746-759 (1995).
65. Sawalha, A. H. and Richardson, B. C.: Pathogenesis. In Tsokos, G. C., Gordon, C. and Smolen, J. S. (eds.): Systemic lupus erythematosus: a companion to rheumatology. Philadelphia, Mosby Elsevier, 2007.
66. Uetrecht, J.: Current trends in drug-induced autoimmunity. Autoimmun. Rev., 4(5): 309-314 (2005).
67. Dedeoglu, F.: Drug-induced autoimmunity. Curr. Opin. Rheumatol., 21(5): 547-551 (2009).
68. Nigen, S., Knowles, S. R. and Shear, N. H.: Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J. Drugs Dermatol., 2(3): 278-299 (2003).
69. Edwards, R. G., Youlten, L. J. and Dewdney, J. M.: Penicillin hypersensitivity: mechanism, diagnosis and management. Indian J. Pediatr., 53(1): 37-44 (1986).
70. Levine, B. B.: Studies on the immunological mechanisms of penicillin allergy. I. Antigenic specificities of guinea-pig skin sensitizing rabbit anti-benzylpenicillin antibodies. Immunology, 7: 527-541 (1964).
71. Gueant-Rodriguez, R. M., Romano, A., Beri-Dexheimer, M., Viola, M., Gaeta, F. and Gueant, J. L.: Gene-gene interactions of IL13 and IL4RA variants in immediate allergic reactions to betalactam antibiotics. Pharmacogenet. Genomics, 16(10): 713-719 (2006).
72. Mathelier-Fusade, P.: Drug-induced urticarias. Clin. Rev. Allergy Immunol., 30(1): 19-23 (2006).
73. Torres, M. J., Mayorga, C. and Blanca, M.: Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic tests. J. Investig. Allergol. Clin. Immunol., 19(2): 80-90 (2009).
74. Fernandez, T. D., Canto, G. and Blanca, M.: Molecular mechanisms of maculopapular exanthema. Curr. Opin. Infect. Dis., 22(3): 272-278 (2009).
75. Fernandez, T. D., Mayorga, C., Torres, M. J., Cornejo-Garcia, J. A., Lopez, S., Chaves, P. et al.: Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs. Allergy, 63(6): 712-719 (2008).
76. Posadas, S. J., Padial, A., Torres, M. J., Mayorga, C., Leyva, L., Sanchez, E. et al.: Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J. Allergy Clin. Immunol., 109(1): 155-161 (2002).
77. Yawalkar, N., Egli, F., Hari, Y., Nievergelt, H., Braathen, L. R. and Pichler, W. J.: Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin. Exp. Allergy, 30(6): 847-855 (2000).
78. Britschgi, M., Steiner, U. C., Schmid, S., Depta, J. P., Senti, G., Bircher, A. et al.: T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J. Clin. Invest., 107(11): 1433-1441 (2001).
79. Chen, X., Tharmanathan, T., Mannargudi, B., Gou, H. and Uetrecht, J. P.: A study of the specificity of lymphocytes in nevirapine-induced skin rash. J. Pharmacol. Exp. Ther., 331(3): 836-841 (2009).
80. Mockenhaupt, M.: Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J. Dtsch. Dermatol. Ges., 7(2): 142-160; quiz 161-162 (2009).
81. Abe, R.: Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. J. Dermatol. Sci., 52(3): 151-159 (2008).
82. Nassif, A., Moslehi, H., Le Gouvello, S., Bagot, M., Lyonnet, L., Michel, L. et al.: Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J. Invest. Dermatol., 123(5): 850-855 (2004).
83. Chung, W. H., Hung, S. I. and Chen, Y. T.: Genetic predisposition of life-threatening antiepileptic-induced skin reactions. Expert Opin. Drug Saf., 9(1): 15-21 (2010).
84. Hung, S. I., Chung, W. H., Liou, L. B., Chu, C. C., Lin, M., Huang, H. P. et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. U.S.A., 102(11): 4134-4139 (2005).
85. Aster, R. H.: Adverse drug reactions affecting blood cells. Handb. Exp. Pharmacol., 196: 57-76 (2010).
86. Salama, A.: Drug-induced immune hemolytic anemia. Expert Opin. Drug Saf., 8(1): 73-79 (2009).
87. Garratty, G.: Immune cytopenia associated with antibiotics. Transfus. Med. Rev., 7(4): 255-267 (1993).
88. Garratty, G.: Immune hemolytic anemia-a primer. Semin. Hematol., 42(3): 119-121 (2005).
89. Garratty, G. and Arndt, P. A.: An update on drug-induced immune hemolytic anemia. Immunohematology, 23(3): 105-119 (2007).
90. Kenney, B. and Stack, G.: Drug-induced thrombocytopenia. Arch. Pathol. Lab. Med., 133(2): 309-314 (2009).
91. Aster, R. H. and Bougie, D. W.: Drug-induced immune thrombocytopenia. N. Engl. J. Med., 357(6): 580-587 (2007).
92. Warkentin, T. E.: Heparin-induced thrombocytopenia: pathogenesis and management. Br. J. Haematol., 121(4): 535-555 (2003).
93. Warkentin, T. E. and Kelton, J. G.: Temporal aspects of heparininduced thrombocytopenia. N. Engl. J. Med., 344(17): 1286-1292 (2001).
94. Aster, R. H.: Can drugs cause autoimmune thrombocytopenic purpura? Semin. Hematol., 37(3): 229-238 (2000).
95. Andres, E., Zimmer, J., Affenberger, S., Federici, L., Alt, M. and Maloisel, F.: Idiosyncratic drug-induced agranulocytosis: Update of an old disorder. Eur. J. Intern. Med., 17(8): 529-535 (2006).
96. Squier, T. L. and Madison, F. W.: Primary granulocytopenia due to hypersensitivity to amidopyrine. J. Allergy, 6(1): 9-16 (1934).
97. Moeschlin, S. and Wagner, K.: Agranulocytosis due to the occurrence of leukocyte-agglutinins; pyramidon and cold agglutinins. Acta Haematol., 8(1-2): 29-41 (1952).
98. Fibbe, W. E., Claas, F. H., Van der Star-Dijkstra, W., Schaafsma, M. R., Meyboom, R. H. and Falkenburg, J. H.: Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br. J. Haematol., 64(2): 363-373 (1986).
99. Akamizu, T., Ozaki, S., Hiratani, H., Uesugi, H., Sobajima, J., Hataya, Y. et al.: Drug-induced neutropenia associated with antineutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity. Clin. Exp. Immunol., 127(1): 92-98 (2002).
100. Stroncek, D. F., Herr, G. P., Maguire, R. B., Eiber, G. and Clement, L. T.: Characterization of the neutrophil molecules identified by quinine-dependent antibodies from two patients. Transfusion, 34(11): 980-985 (1994).
101. Guest, I., Sokoluk, B., MacCrimmon, J. and Uetrecht, J.: Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology, 131(1): 53-65 (1998).
102. Uetrecht, J. P.: Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis. Drug Saf., 7 Suppl. 1: 51-56 (1992).
103. Gardner, I., Leeder, J. S., Chin, T., Zahid, N. and Uetrecht, J. P.: A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol., 53(6): 999-1008 (1998).
104. Yunis, J. J., Corzo, D., Salazar, M., Lieberman, J. A., Howard, A. and Yunis, E. J.: HLA associations in clozapine-induced agranulocytosis. Blood, 86(3): 1177-1183 (1995).
105. Williams, D. P., Pirmohamed, M., Naisbitt, D. J., Uetrecht, J. P. and Park, B. K.: Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol. Pharmacol., 58(1): 207-216 (2000).
106. Iverson, S., Kautiainen, A., Ip, J. and Uetrecht, J. P.: Effect of clozapine on neutrophil kinetics in rabbits. Chem. Res. Toxicol., Jun 17 (2010).
107. Young, N. S.: Autoimmunity and its treatment in aplastic anemia. Ann. Intern. Med., 126(2): 166-168 (1997).
108. Young, N. S., Scheinberg, P. and Calado, R. T.: Aplastic anemia. Curr. Opin. Hematol., 15(3): 162-168 (2008).
109. Young, N. S.: Acquired aplastic anemia. Ann. Intern. Med., 136(7): 534-546 (2002).
110. Young, N. and Alter, B. P.: Aplastic Anemia: Acquired and Inherited. London, W. B. Saunders Company, 1994.
111. Keohane, E. M.: Acquired aplastic anemia. Clin. Lab. Sci., 17(3): 165-171 (2004).
112. Ostapowicz, G., Fontana, R. J., Schiodt, F. V., Larson, A., Davern, T. J., Han, S. H. et al.: Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med., 137(12): 947-954 (2002).
113. Temple, R. J. and Himmel, M. H.: Safety of newly approved drugs: implications for prescribing. JAMA, 287(17): 2273-2275 (2002).
114. Lawrenson, R. A., Seaman, H. E., Sundstrom, A., Williams, T. J. and Farmer, R. D.: Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf., 23(4): 333-349 (2000).
115. Keisu, M. and Andersson, T. B.: Drug-induced liver injury in humans: The case of ximelagatran. In: Uetrecht, J. P. (ed.): Mechanisms of Adverse Drug Reactions. Heidelberg, Springer- Verlag, 2010, pp. 407-418.
116. Zimmerman, H.: Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia, Lippincott Williams & Wilkins, 1999.
117. Obermayer-Straub, P., Strassburg, C. P. and Manns, M. P.: Target proteins in human autoimmunity: cytochromes P450 and UDP-glucuronosyltransferases. Can. J. Gastroenterol., 14(5): 429-439 (2000).
118. Liu, Z. X. and Kaplowitz, N.: Immune-mediated drug-induced liver disease. Clin. Liver Dis., 6(3): 467-486 (2002).
119. Kleiner, D. E.: The pathology of drug-induced liver injury. Semin. Liver Dis., 29(4): 364-372 (2009).
120. Chien, R. N., Sheen, I. S. and Liaw, Y. F.: Unintentional rechallenge resulting in a causative relationship between ketoconazole and acute liver injury. Int. J. Clin. Pract., 57(9): 829-830 (2003).
121. Maddrey, W. C. and Boitnott, J. K.: Isoniazid hepatitis. Ann. Intern. Med., 79(1): 1-12 (1973).
122. Roth, R. A., Luyendyk, J. P., Maddox, J. F. and Ganey, P. E.: Inflammation and drug idiosyncrasy-is there a connection? J. Pharmacol. Exp. Ther., 307(1): 1-8 (2003).
123. Ong, M. M., Latchoumycandane, C. and Boelsterli, U. A.: Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol. Sci., 97(1): 205-213 (2007).
124. Fujimoto, K., Kumagai, K., Ito, K., Arakawa, S., Ando, Y., Oda, S. et al.: Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. Toxicol. Pathol., 37(2): 193-200 (2009).
125. McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y. et al.: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med., 333(17): 1099-1105 (1995).
126. Van Huyen, J. P., Landau, A., Piketty, C., Belair, M. F., Batisse, D., Gonzalez-Canali, G. et al.: Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy. Am. J. Clin. Pathol., 119(4): 546-555 (2003).
127. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R. and de Graaf, D.: Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci., 105(1): 97-105 (2008).
128. Uetrecht, J.: Immunoallergic drug-induced liver injury in humans. Semin. Liver Dis., 29(4): 383-392 (2009).
129. Crispe, I. N.: The liver as a lymphoid organ. Annu. Rev. Immunol., 27: 147-163 (2009).
130. Sheth, K. and Bankey, P.: The liver as an immune organ. Curr. Opin. Crit. Care, 7(2): 99-104 (2001).
131. Wick, M. J., Leithauser, F. and Reimann, J.: The hepatic immune system. Crit. Rev. Immunol., 22(1): 47-103 (2002).
132. Racanelli, V. and Rehermann, B.: The liver as an immunological organ. Hepatology, 43(2 Suppl. 1): S54-S62 (2006).
133. Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K.: IL-17 and Th17 Cells. Annu. Rev. Immunol., 27: 485-517 (2009).
134. Kobayashi, E., Kobayashi, M., Tsuneyama, K., Fukami, T., Nakajima, M. and Yokoi, T.: Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol. Sci., 111(2): 302-310 (2009).
135. Li, J., Zhu, X., Liu, F., Cai, P., Sanders, C., Lee, W. M. et al.: Cytokine and autoantibody patterns in acute liver failure. J. Immunotoxicol., (2009).